Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Products under Development by Stage of Development | 9 | 1 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Products under Development by Therapy Area | 10 | 1 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Products under Development by Indication | 11 | 1 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Products under Development by Companies | 14 | 2 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Therapeutics Assessment | 16 | 4 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 1 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Companies Involved in Therapeutics Development | 20 | 15 |
| Amgen Inc. | 20 | 1 |
| Array BioPharma Inc. | 21 | 1 |
| Astellas Pharma Inc. | 22 | 1 |
| CymaBay Therapeutics, Inc. | 23 | 1 |
| Daiichi Sankyo Company, Limited | 24 | 1 |
| F. Hoffmann-La Roche Ltd. | 25 | 1 |
| GlaxoSmithKline Plc | 26 | 1 |
| Hyundai Pharmaceutical Co., Ltd. | 27 | 1 |
| LG Life Science LTD. | 28 | 1 |
| Merck &Co., Inc. | 29 | 1 |
| Novartis AG | 30 | 1 |
| Sanwa Kagaku Kenkyusho Co., Ltd. | 31 | 1 |
| Taisho Pharmaceutical Holdings Co., Ltd. | 32 | 1 |
| Takeda Pharmaceutical Company Limited | 33 | 1 |
| Yuhan Corporation | 34 | 1 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Drug Profiles | 35 | 21 |
| 17-i Drug Profile | 35 | 1 |
| ARRY-981 Drug Profile | 36 | 1 |
| AS-1669058 Drug Profile | 37 | 1 |
| DA-1241 Drug Profile | 38 | 1 |
| DS-8500 Drug Profile | 39 | 2 |
| GSK-2041706 Drug Profile | 41 | 1 |
| HD-0471042 Drug Profile | 42 | 1 |
| HD-0471953 Drug Profile | 43 | 1 |
| HOB-047 Drug Profile | 44 | 1 |
| LC-34AD3 Drug Profile | 45 | 1 |
| MBX-2982 Drug Profile | 46 | 1 |
| Small Molecule to Agonize GPR119 for Type 2 Diabetes Drug Profile | 47 | 1 |
| Small Molecule to Agonize GPR119 for Type II Diabetes Drug Profile | 48 | 1 |
| Small Molecule to Agonize GPR119 for Undisclosed Indication Drug Profile | 49 | 1 |
| Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication Drug Profile | 50 | 1 |
| Small Molecules to Agonize GPR119 for Metabolic Disorders Drug Profile | 51 | 1 |
| Small Molecules to Agonize GPR119 for Type II Diabetes Drug Profile | 52 | 1 |
| Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes Drug Profile | 53 | 1 |
| Small Molecules to Agonize GPR119 Receptor for Type II Diabetes Drug Profile | 54 | 1 |
| YH-18420 Drug Profile | 55 | 1 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Dormant Projects | 56 | 2 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Discontinued Products | 58 | 1 |
| Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Featured News &Press Releases | 59 | 2 |
| Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round | 59 | 1 |
| Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982 | 59 | 1 |
| Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982 | 60 | 1 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |